ESMO Congress 2022
ESMO Congress 2022 Paris Expo Porte de Versailles
Oxford BioDynamics is proud to be attending the ESMO Congress 2022. Come see us at booth #419 to speak with our experts directly.
- Contact us to meet and learn about an innovation that will help transform how immunotherapy is recommended and administered.
Which patients will respond to checkpoint inhibitors?
Patients being considered for or currently receiving checkpoint inhibitor therapies. This is the only test that can predict an individual’s likelihood of response to checkpoint inhibitors and provides useful information at the cross-roads of a patient's treatment journey.
Non-predictive diagnostic testing1
ICI response prediction before treatment2
1: Hunter, E. et al. (2021), Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications. MedRxiv (2021) doi:10.1101/2021.12.21.21268094;
2: Hunter, E. et al. (2019), SITC, J. Immunotherapy Cancer 7(282) P142 & P143